title: Immunotherapy for the treatment of prostate cancer.
abstract: Failure of immune surveillance has a prominent role in tumorigenesis. Cancerous cells can evade T-cell responses to tumor-associated antigens by multiple mechanisms. Active immunotherapy aims to stimulate the immune response against cancer cells. Unlike normal prostate tissue, prostate cancer is not ignored by the immune system, as shown by the presence of tumor infiltrating lymphocytes. This characteristic renders prostate cancer particularly suitable for immunotherapy. The existence of well-defined antigens, largely limited to prostate tissue, allows prostate cancer cells to be targeted without the risk of systemic autoimmune reactions, as autoimmunity specifically directed at the prostate is the goal of prostate cancer immunotherapy. Active immunotherapy directed towards prostate cancer can be conducted using multiple strategies, involving dendritic cells, whole-cell vaccines, viral vectors, DNA-based and peptide-based agents, as well as immunostimulatory agents. The only FDA-approved immunotherapy for prostate cancer is the dendritic-cell-based agent Sipuleucel-T, which yielded an advantage in overall survival, but not in progression-free survival in a phase III trial. We present the clinical developments in the field of immunotherapy and critically analyze methodological issues related to the evaluation of tumor responses to immunotherapy, trial design, and surrogate end points.
authors: Department of Endocrinology and Medical Oncology, Genitourinary Cancer Section, University Federico II, Via Pansini 5, Naples, Italy. giuseppedilorenzoncol@hotmail.com
authors: Giuseppe
authors: G
authors: Di Lorenzo
authors: Carlo
authors: C
authors: Buonerba
authors: Philip W
authors: PW
authors: Kantoff
references: J Gene Med. 2007 Jul;9(7):547-60
references: 17514769
references: J Natl Cancer Inst. 2010 Sep 22;102(18):1388-97
references: 20826737
references: J Urol. 2007 Oct;178(4 Pt 1):1515-20
references: 17707059
references: J Clin Oncol. 2009 Sep 1;27(25):4047-54
references: 19636017
references: J Clin Oncol. 2010 Mar 1;28(7):1099-105
references: 20100959
references: Urol Clin North Am. 2010 Feb;37(1):121-9, Table of Contents
references: 20152525
references: Prostate. 2006 Jun 1;66(8):811-21
references: 16482569
references: Oncol Res. 2007;16(7):341-9
references: 17518272
references: Br J Cancer. 2004 Aug 2;91(3):541-3
references: 15266325
references: N Engl J Med. 2010 Jul 29;363(5):479-81
references: 20818868
references: J Pharm Pharm Sci. 2007;10(2):144-52
references: 17706173
references: Eur J Cancer. 1994;30A(12):1797-803
references: 7880609
references: J Clin Oncol. 2006 Jul 1;24(19):3089-94
references: 16809734
references: Cancer Immunol Immunother. 2000 Dec;49(10):517-29
references: 11129322
references: N Engl J Med. 2010 Nov 11;363(20):1966-7; author reply 1968
references: 21067391
references: Immunity. 2010 Oct 29;33(4):504-15
references: 21029961
references: N Engl J Med. 2010 Aug 19;363(8):711-23
references: 20525992
references: Clin Cancer Res. 2006 Feb 15;12(4):1260-9
references: 16489082
references: J Immunother. 2008 Jul-Aug;31(6):577-85
references: 18528296
references: Clin Cancer Res. 2011 Mar 15;17(6):1571-81
references: 21159885
references: Immunity. 2001 Feb;14(2):145-55
references: 11239447
references: Cancer Sci. 2010 Mar;101(3):601-8
references: 20128819
references: Oncologist. 2006 May;11(5):451-62
references: 16720845
references: BJU Int. 2006 Nov;98(5):989-95
references: 16879440
references: Clin Cancer Res. 2007 Jul 1;13(13):3883-91
references: 17606721
references: Cancer. 2010 Feb 15;116(4 Suppl):1075-83
references: 20127956
references: Blood. 2010 Sep 9;116(10):1726-33
references: 20519625
references: Invest New Drugs. 2009 Aug;27(4):379-86
references: 18931824
references: Prostate. 2007 Apr 1;67(5):500-8
references: 17262804
references: Cancer Immunol Immunother. 2010 May;59(5):663-74
references: 19890632
references: Cancer Res. 2009 Jan 15;69(2):609-15
references: 19147575
references: Nat Rev Cancer. 2008 Feb;8(2):108-20
references: 18219306
references: Drugs. 2010 May 28;70(8):983-1000
references: 20481655
references: Cancer Res. 1999 Nov 15;59(22):5800-7
references: 10582702
references: Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14565-70
references: 11734652
references: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references: 20610543
references: JAMA. 1999 May 5;281(17):1591-7
references: 10235151
references: Cancer. 2008 Sep 1;113(5):975-84
references: 18646045
references: Ann Oncol. 2010 Oct;21(10):1944-1951
references: 20237004
references: Nat Rev Immunol. 2010 Aug;10(8):580-93
references: 20651745
references: Cancer Immunol Immunother. 2006 Sep;55(9):1033-42
references: 16283303
references: Hum Gene Ther. 2009 Dec;20(12):1641-51
references: 19671000
references: J Clin Oncol. 2008 Mar 1;26(7):1148-59
references: 18309951
references: Cancer Res. 2007 Aug 1;67(15):7450-7
references: 17671215
references: Hum Gene Ther. 2009 Nov;20(11):1269-78
references: 19619001
references: Cancer Immunol Immunother. 2007 Dec;56(12):1921-30
references: 17619878
references: N Engl J Med. 2010 Jul 29;363(5):411-22
references: 20818862
references: Clin Cancer Res. 2008 Jul 15;14(14):4526-31
references: 18628467
references: Nat Rev Drug Discov. 2010 Jul;9(7):513-4
references: 20592741
references: J Immunol. 2005 Aug 15;175(4):2741-53
references: 16081852
references: J Urol. 2008 Nov;180(5):2011-7; discussion 2017-8
references: 18801509
references: J Immunother. 2010 Jul-Aug;33(6):639-47
references: 20551832
references: Adv Immunol. 2006;90:51-81
references: 16730261
references: Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3394-401
references: 16740763
references: Cancer Treat Rep. 1977 Mar-Apr;61(2):217-22
references: 326398